Add two of the same products to your cart, and get the second one FREE!
4 products
4 products
Sale
QUICK SHOP
CBD+Relief Cream 300mg 2oz
CBD+Relief: Revolutionary Pain Relief Salve
Looking for more CBD products? See our CBD Oil, CBD Gummies and CBD Capsules!
CBD+Relief from Axis Labs is a revolutionary relief cream infused with the power of CBD from Full Spectrum hemp extract. Additionally, we’ve added pain naturally relieving and effective topical ingredients including peppermint and ginger that offers impressive results after application.
Axis Labs formulates its CBD-based relief cream using natural, non-GMO full spectrum hemp oil. Derived from U.S. grown industrial hemp, the CBD offered by Axis Labs is non-psychoactive and compliant with the Agricultural Act of 2014, also known as the 2014 Farm Bill, as well as the 2018 Farm Bill.
CBD is remarkable for its natural healing properties, without leaving users with an unwanted sense of being “high.” That’s because we derive our CBD from hemp, which has a practically zero percent THC count. Enjoy the benefits of CBD with our pain relief cream.
Available in a 2 oz jar, CBD+ Relief is crafted to achieve the highest potency and quality and can be had without a doctor’s prescription.
- Available in 2 oz Jar
- 300mg CBD per Jar
- Very pleasant aroma with aromatherapeutic benefits
- Third Party Tested for Potency, contaminants, parasites
Ingredients: Aloe Barbadensis (Aloe Vera) Leaf Juice*, Purified Water (Aqua), Vegetable Glycerin, Ricinus Communis (Castor) Seed Oil, Cetearyl Alcohol, Caprylic/Capric Triglyceride, Sodium Acrylates Copolymer, Arnica Montana Flower Extract, Cannabis Sativa (Whole Plant Hemp) Extract, Cetyl Palmitate, Lecithin, Sorbitan Palmitate, Hippophae Rhamnoides Fruit Oil*, Zingiber Officinale (Ginger) Root Oil*, Benzyl Alcohol, Oryza Sativa (Rice) Bran Extract, Rosmarinus Officinalis (Rosemary) Leaf Extract, Helianthus Annuus (Sunflower) Extract, Camellia Sinensis (Green Tea) Leaf Extract, Phytic Acid, Xanthan Gum, Epilobium Angustifolium Extract, Benzoic Acid, Sorbitan Oleate, Mentha Piperita (Peppermint) Oil*, Beta Carotene, Dehydroacetic Acid, Tocopherol. *Organic
WARNING: KEEP OUT OF REACH OF CHILDREN. Do not use if you are pregnant or nursing. Consult your healthcare professional before using this or any type of dietary supplements. If the user is subject to cannabinoid testing, consult with the requiring entity before taking this or any other dietary supplement.
MYODEX Advanced Testosterone Modulator 60 Capsules
Myodex: Advanced Testosterone Modulator
Myodex is formulated to increase your natural Free Testosterone levels by inhibiting its conversion into DHT and Estrogen.
Testosterone - it's a word that sparks visions of virility, athletic prowess and strong, lean muscles. It's the stuff that makes men... "men." However, supporting testosterone levels alone simply isn't enough.
Here's why: As testosterone is produced, two other "tag along" hormones try to "join the ride." We're talking DHT and Estrogen here. The process works something like a rheostat; as one hormone (testosterone) increases or decreases, related hormones rise and fall respectively. This is a normal biological function. However, this "normal biological function" is not always desirable. Let's explore this concept a bit further.
IT'S NOT A PRETTY SIGHT
DHT (dihydrotestosterone) is a powerful "spinoff" hormone of testosterone. Therefore, as testosterone is produced DHT is likely to rise. Here's the problem - DHT essentially "attacks" hair follicles. Over time, DHT "stressed" hair follicles can no longer maintain normal hair production. This is a primary culprit of male pattern baldness, otherwise known as the dreaded "chrome dome."
If that weren't bad enough, testosterone support can result in higher levels of Estrogen.
AN ENZYMATIC ASSAULT
So, you're probably wondering specifically how testosterone support can result in higher levels of DHT and Estrogen. After all, supporting the root cause of hormonal balances would likely allow for peak testosterone bioavailability. Good thinking, you're already considering the potential benefits of supporting healthy levels these "other" hormones.
Once produced, DHT and Estrogen are already "out there." Essentially, it's too late to get them under control. Therefore, the answer to managing them is to address and overcome the underlying factors that impact their production. The underlying "factors" are the enzymes 5a reductase and aromatase. 5a reductase converts testosterone into "shiny head"-promoting DHT. Aromatase converts testosterone into estrogen.
Undoubtedly, promoting a healthy balance of 5a reductase and Aromatase enzymes would likely allow for optimal testosterone production and bioavailability – while also supporting a healthy balance of DHT and Estrogen.*
ENTER... MYODEX
MYODEX is a one of a kind, Advanced Testosterone Modulator. "Oh, sure", you may be thinking, "This is just another testosterone booster." Nothing could be further from the truth. You see, "typical" testosterone boosters are designed to do just that – support testosterone levels. However, as we have revealed, boosting testosterone alone is not enough.
What makes MYODEX so unique is how it goes about supporting optimal testosterone flow and bioavailability.*
MYODEX is scientifically formulated to help boost testosterone by simultaneously helping reduce its conversion into DHT and Estrogen!*
By helping to counter 5a reductase and Aromatase, MYODEX directly addresses and resolves the limiting factors that reduce full testosterone functionality.*
Let's make this really simple. MYODEX is formulated to "hold back" the limiting factors, DHT and Estrogen, to promote production of Testosterone.* By harnessing this dual-force approach, MYODEX has unleashed the potential of your body to support Testosterone levels.*
The power of MYODEX is locked in the fully efficacious, advanced ProtectErone™ Proprietary Blend. ProtectErone™ houses the Estrogen reducing Complex and the DHT Inhibiting Complex.*
THE SCIENCE
The Estrogen Inhibiting Complex features full strength Quercetin and DIM.
Quercetin is a powerful flavonoid (a compound that gives plants their bright coloration) that functions as an antioxidant to help reduce the effects of free radicals and may even help support prostate health.* However, one of the more direct benefits of quercetin, relative to testosterone support, is its purported effect on reducing Aromatase enzymes.* Simply put - inhibition of Aromatase may promote testosterone production and less estrogen production.*
Axis Labs didn't stop there. A precise dose of DIM was incorporated to offer the most effective formula possible. DIM (Di-Indoly Methane) is a nutrient found naturally occurring in cruciferous vegetables. Examples include broccoli, kale, cabbage and Brussels sprouts. In simple terms, DIM may work by competing for metabolism with Estrogen.* Basically, it's one or the other. With DIM present in the system, Estrogen may "lose out."*
THE BOTTOM LINE
The DHT Inhibiting Complex is thoroughly loaded with Beta Sitosterol and Saw Palmetto.
Testosterone is hailed the "king of anabolic hormones." Adequate levels help promote lean mass, bone mineral density, and even positive mood.* When testosterone is at optimal levels, it helps support greater strength, vitality, mood and overall health.* With Axis Labs MYODEX, male support has never been more achievable.* MYODEX was expressly formulated to boost testosterone while helping reduce its conversion into DHT and Estrogen.* With MYODEX, you may support testosterone, healthy DHT and Estrogen conversion and promote vitality.*
Bottom line - the question isn't, "Why do I need this product?" it's "How soon can I start MYODEX?"
References:
Abdelbaqi, K., N. Lack, et al. "Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells." Prostate 71(13): 1401-12.
Angwafor, F., 3rd and M. L. Anderson (2008). "An open label, dose response study to determine the effect of a dietary supplement on dihydrotestosterone, testosterone and estradiol levels in healthy males." J Int Soc Sports Nutr 5: 12.
Berges, R. R., J. Windeler, et al. (1995). "Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group." Lancet 345(8964): 1529-32.
Brown, G. A., M. D. Vukovich, et al. (2000). "Effects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young men." Int J Sport Nutr Exerc Metab 10(3): 340-59.
Cabeza, M., E. Bratoeff, et al. (2003). "Effect of beta-sitosterol as inhibitor of 5 alpha-reductase in hamster prostate." Proc West Pharmacol Soc 46: 153-5.
Canivenc-Lavier, M. C., M. F. Vernevaut, et al. (1996). "Comparative effects of flavonoids and model inducers on drug-metabolizing enzymes in rat liver." Toxicology 114(1): 19-27.
Cho, H. J., S. Y. Park, et al. "3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model." Mol Carcinog 50(2): 100-12.
Gong, Y., H. Sohn, et al. (2006). "3,3'-Diindolylmethane is a novel mitochondrial H(+)-ATP synthase inhibitor that can induce p21(Cip1/Waf1) expression by induction of oxidative stress in human breast cancer cells." Cancer Res 66(9): 4880-7.
Khan, S. I., J. Zhao, et al. "Potential utility of natural products as regulators of breast cancer-associated aromatase promoters." Reprod Biol Endocrinol 9: 91.
Kim, Y. H., H. S. Kwon, et al. (2009). "3,3'-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice." Inflamm Bowel Dis 15(8): 1164-73.
Krazeisen, A., R. Breitling, et al. (2001). "Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5." Mol Cell Endocrinol 171(1-2): 151-62.
Krazeisen, A., R. Breitling, et al. (2002). "Human 17beta-hydroxysteroid dehydrogenase type 5 is inhibited by dietary flavonoids." Adv Exp Med Biol 505: 151-61.
Lacey, M., J. Bohday, et al. (2005). "Dose-response effects of phytoestrogens on the activity and expression of 3beta-hydroxysteroid dehydrogenase and aromatase in human granulosa-luteal cells." J Steroid Biochem Mol Biol 96(3-4): 279-86.
Le, H. T., C. M. Schaldach, et al. (2003). "Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells." J Biol Chem 278(23): 21136-45.
Lowe, F. C. and J. C. Ku (1996). "Phytotherapy in treatment of benign prostatic hyperplasia: a critical review." Urology 48(1): 12-20.
Marks, L. S., D. L. Hess, et al. (2001). "Tissue effects of saw palmetto and finasteride: use of biopsy cores for in situ quantification of prostatic androgens." Urology 57(5): 999-1005.
McNicholas, T. and R. Kirby (2011). "Benign prostatic hyperplasia and male lower urinary tract symptoms (LUTS)." Clin Evid (Online) 2011.
Monteiro, R., A. Faria, et al. (2008). "Red wine interferes with oestrogen signalling in rat hippocampus." J Steroid Biochem Mol Biol 111(1-2): 74-9.
Moon, Y. J., X. Wang, et al. (2006). "Dietary flavonoids: effects on xenobiotic and carcinogen metabolism." Toxicol In Vitro 20(2): 187-210.
Oshima, M. and Y. Gu (2003). "Pfaffia paniculata-induced changes in plasma estradiol-17beta, progesterone and testosterone levels in mice." J Reprod Dev 49(2): 175-80.
Pais, P. "Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II." Adv Ther 27(8): 555-63.
Pelissero, C., M. J. Lenczowski, et al. (1996). "Effects of flavonoids on aromatase activity, an in vitro study." J Steroid Biochem Mol Biol 57(3-4): 215-23.
Prager, N., K. Bickett, et al. (2002). "A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia." J Altern Complement Med 8(2): 143-52.
Rice, S., H. D. Mason, et al. (2006). "Phytoestrogens and their low dose combinations inhibit mRNA expression and activity of aromatase in human granulosa-luteal cells." J Steroid Biochem Mol Biol 101(4-5): 216-25.
Rogan, E. G. (2006). "The natural chemopreventive compound indole-3-carbinol: state of the science." In Vivo 20(2): 221-8.
Sanderson, J. T., J. Hordijk, et al. (2004). "Induction and inhibition of aromatase (CYP19) activity by natural and synthetic flavonoid compounds in H295R human adrenocortical carcinoma cells." Toxicol Sci 82(1): 70-9.
Sarkar, F. H. and Y. Li (2004). "Indole-3-carbinol and prostate cancer." J Nutr 134(12 Suppl): 3493S-3498S.
Sarkar, F. H. and Y. Li (2009). "Harnessing the fruits of nature for the development of multi-targeted cancer therapeutics." Cancer Treat Rev 35(7): 597-607.
Sarkar, F. H., Y. Li, et al. (2009). "Cellular signaling perturbation by natural products." Cell Signal 21(11): 1541-7.
Sepkovic, D. W., J. Stein, et al. (2009). "Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model." Cancer Epidemiol Biomarkers Prev 18(11): 2957-64.
Suzuki, M., Y. Ito, et al. (2009). "Pharmacological effects of saw palmetto extract in the lower urinary tract." Acta Pharmacol Sin 30(3): 227-81.
Upadhyay, K., N. K. Gupta, et al. (2012). "Development and characterization of phyto-vesicles of beta-sitosterol for the treatment of androgenetic alopecia." Arch Dermatol Res 304(7): 511-9.
Vivar, O. I., C. L. Lin, et al. (2009). "3,3'-Diindolylmethane induces a G(1) arrest in human prostate cancer cells irrespective of androgen receptor and p53 status." Biochem Pharmacol 78(5): 469-76.
Wang, T. T., M. J. Milner, et al. (2006). "Estrogen receptor alpha as a target for indole-3-carbinol." J Nutr Biochem 17(10): 659-64.
Whitehead, S. A. and M. Lacey (2003). "Phytoestrogens inhibit aromatase but not 17beta-hydroxysteroid dehydrogenase (HSD) type 1 in human granulosa-luteal cells: evidence for FSH induction of 17beta-HSD." Hum Reprod 18(3): 487-94.
Wu, G. X., Y. X. Lin, et al. (2003). "[An experimental study(II) on the inhibition of prostatic hyperplasia by extract of seeds of Brassica alba]." Zhongguo Zhong Yao Za Zhi 28(7): 643-6.
Yang, J. H., T. P. Kondratyuk, et al. "Bioactive compounds from the fern Lepisorus contortus." J Nat Prod 74(2): 129-36.
